New combined treatment shows promise in hepatocellular carcinoma

June 27, 2018

Researchers from the Metabolism and Cancer group at the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr Sara Kozma, have unveiled a new potential combined treatment for Hepatocellular Carcinoma (HCC), the second cause of cancer mortality worldwide. The combination of mTOR inhibitors together with the mitochondrial inhibitor Phenformin has shown positive results in in vitro HCC cells, leading to a striking increase in tumor-bearing mice overall survival, which has been recently reported in Clinical Cancer Research.

"Currently available therapeutic options for HCC are very limited and offer poor outcomes, prompting the search for new therapeutic approaches", explains Dr. Kozma, last author of the article. "Inhibitors of the mTOR pathway had already been explored as an alternative treatment, given that this pathway is hyperactivated in most HCCs, but they showed little clinical efficacy. However, as recent data suggested that mTOR inhibitors may promote cancer cell survival by maintaining mitochondrial oxidation and/or autophagy, we set out to examine their use combined with inhibitors of mitochondrial activity." she adds.

In their study, researchers show that treatment of HCC cells in vitro with Phenformin, a mitochondrial Complex1 inhibitor, causes a metabolic shift to glycolysis, mitochondrial dysfunction and fragmentation. "These changes sensitize orthotopic liver tumors in mice to dual inhibition of mTOR, which improves tumor-bearing mice overall survival", says Dr. Sonia Veiga, first author of the Clinical Cancer Research paper.

"Given the recent approval of Phenformin in a clinical trial for melanoma, it will be exciting to explore this regimen clinically in HCC", says Dr. Kozma. According to Dr. Veiga, next steps include testing this combination in human samples thanks to collaboration with Bellvitge Unversity Hospital and the Catalan Institute of Oncology, as well as comparing the results obtained with those of current treatments for HCC.
-end-


IDIBELL-Bellvitge Biomedical Research Institute

Related Hepatocellular Carcinoma Articles from Brightsurf:

Oncotarget: Characterization of porcine hepatocellular carcinoma for liver cancer
Volume 11, Issue 28 of Oncotarget features ''Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation'' by Gaba et, al. which reported that reliable development of Oncopig HCC cell lines was demonstrated through hepatocyte isolation and Cre recombinase exposure across 15 Oncopigs.

Oncotarget: GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma
The cover for issue 36 of Oncotarget features Figure 7, 'Knockdown of APOBEC3B is associated with a lower tumor growth in an adrenocortical carcinoma xenograft mouse model,' by Gara, et al. which reported that the role of APOBEC3B in adrenocortical carcinoma and the mechanisms through which its expression is regulated in cancer are not fully understood.

A 3D biofabricated cutaneous squamous cell carcinoma tissue model
The cover for issue 27 of Oncotarget features Figure 4, ''(A) Bimodal imaging examples of control and treated tumors (red) before and after the treatment period,'' by Browning, et al. and reported that the authors developed a 3-dimensional bioprinted skin model of cutaneous squamous cell carcinoma (cSCC) tumors together with a microscopy assay to test chemotherapeutic effects in tissue.

Contrast-enhanced ultrasound predicts nodule transformation to hepatocellular carcinoma
An article published ahead-of-print in the January 2020 issue of the American Journal of Roentgenology has identified sonographic biomarkers that can predict eventual malignant transformation of pathologically confirmed cirrhotic nodules for patients at risk for hepatocellular carcinoma (HCC).

Lifetime indoor tanning associated with squamous cell carcinoma cancer
This observational study used data from nearly 160,000 women in Norway to examine lifetime indoor tanning and risk of squamous cell carcinoma, one of the most common types of cancer worldwide.

Aspirin improves liver function after embolization of hepatocellular carcinoma
Aspirin therapy is associated with both improved liver function test results and survival after transarterial embolization for hepatocellular carcinoma, according to an ahead-of-print article by F.

Percutaneous ablation vs. surgery for hepatocellular carcinoma
Compared to surgery, percutaneous liver ablation interventions (IRs) in patients with hepatocellular carcinoma (HCC) are associated with lower inhospital mortality, length of hospital stay (LOS), and hospitalization costs, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, Hawaii.

Osteopontin: A new emerging role in HCV-related hepatocellular carcinoma
A research team based in Japan led by Kanazawa University has demonstrated the effect of osteopontin on hepatitis C virus replication and interferon signaling in cancer stem cells.

New combined treatment shows promise in hepatocellular carcinoma
New combined treatment shows promise in Hepatocellular Carcinoma. A combination of mTOR inhibitors and Phenformin leads to an increase in overall survival.

Screening for hepatocellular carcinoma in patients with hepatitis C-related cirrhosis achieving sustained virological response is likely to be cost effective
A Canadian study suggests that biannual or annual ultrasound screening for HCC is likely to be cost effective after a sustained virological response in those with hepatitis C-related cirrhosis, but not in those with advanced fibrosis without cirrhosis.

Read More: Hepatocellular Carcinoma News and Hepatocellular Carcinoma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.